

New Study Announcement

High Dose Vitamin C (ascorbic acid) in combination with standard chemotherapy for newly diagnosed, Metastatic Cancer of the Pancreas

This study is a collaborative effort between the Jefferson-Myrna Brind Center of Integrative Medicine and the Jefferson Kimmel Cancer Center, Thomas Jefferson University and Hospital.

Formal Title: Phase I, Open Label, Dose Escalating Study of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in the Treatment of Metastatic Pancreatic Cancer (IRB# 09D.99; Principal Investigator- Daniel A. Monti, MD)

The primary goal of this study is to test the safety and tolerability of intravenous Vitamin C in combination with standard chemotherapy for newly diagnosed, metastatic, pancreatic cancer. Secondly, the study will assess progression of the disease.

Some of the requirements include:

- Males and females who are at least 18 years of age
- Confirmed diagnosis of pancreatic adenocarcinoma
- Metastatic Disease that is measurable by CT scan or MRI
- No previous chemotherapy or radiation
- Able to commit to three infusions a week for eight weeks (note that Vitamin C infusions will be free of charge for study participants)

For full requirements to enter the study, contact **Study Coordinator Dr. Joel Edman at (215) 955-2839** or email **Joel.Edman@jefferson.edu**